Concepts (136)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bipolar Disorder | 14 | 2023 | 347 | 3.590 |
Why?
|
| Aggression | 8 | 2021 | 225 | 1.090 |
Why?
|
| Antimanic Agents | 4 | 2019 | 37 | 1.090 |
Why?
|
| Valproic Acid | 6 | 2011 | 164 | 1.020 |
Why?
|
| Antipsychotic Agents | 4 | 2024 | 375 | 0.940 |
Why?
|
| Integrative Medicine | 1 | 2023 | 12 | 0.850 |
Why?
|
| Fatty Acids, Omega-3 | 1 | 2023 | 69 | 0.800 |
Why?
|
| Attention | 2 | 2020 | 196 | 0.740 |
Why?
|
| Emotions | 3 | 2023 | 361 | 0.740 |
Why?
|
| Yoga | 1 | 2020 | 12 | 0.700 |
Why?
|
| Meditation | 1 | 2020 | 17 | 0.690 |
Why?
|
| Lithium Compounds | 1 | 2019 | 14 | 0.680 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 4 | 2020 | 216 | 0.660 |
Why?
|
| Facial Expression | 1 | 2019 | 28 | 0.640 |
Why?
|
| Stress, Psychological | 3 | 2020 | 556 | 0.570 |
Why?
|
| Adolescent | 27 | 2024 | 19131 | 0.540 |
Why?
|
| Conduct Disorder | 5 | 2011 | 32 | 0.530 |
Why?
|
| Cerebral Cortex | 1 | 2019 | 448 | 0.510 |
Why?
|
| Suicide, Attempted | 3 | 2021 | 132 | 0.480 |
Why?
|
| Child | 24 | 2024 | 24263 | 0.450 |
Why?
|
| Attention Deficit and Disruptive Behavior Disorders | 5 | 2010 | 44 | 0.450 |
Why?
|
| Corpus Callosum | 2 | 2022 | 98 | 0.430 |
Why?
|
| Mood Disorders | 2 | 2023 | 125 | 0.390 |
Why?
|
| Suicidal Ideation | 4 | 2022 | 215 | 0.380 |
Why?
|
| Nerve Fibers | 1 | 2012 | 72 | 0.380 |
Why?
|
| Obsessive-Compulsive Disorder | 3 | 2024 | 772 | 0.360 |
Why?
|
| GABA Agents | 2 | 2010 | 21 | 0.350 |
Why?
|
| Risperidone | 1 | 2006 | 60 | 0.260 |
Why?
|
| Emergency Service, Hospital | 3 | 2022 | 1075 | 0.250 |
Why?
|
| Humans | 29 | 2024 | 123254 | 0.240 |
Why?
|
| Anticonvulsants | 1 | 2005 | 376 | 0.210 |
Why?
|
| Autoimmune Diseases | 1 | 2024 | 250 | 0.200 |
Why?
|
| Streptococcal Infections | 1 | 2024 | 244 | 0.200 |
Why?
|
| Male | 16 | 2024 | 60310 | 0.190 |
Why?
|
| Parents | 3 | 2024 | 1033 | 0.180 |
Why?
|
| Kynurenine | 1 | 2020 | 21 | 0.180 |
Why?
|
| White Matter | 1 | 2022 | 180 | 0.180 |
Why?
|
| Case-Control Studies | 2 | 2020 | 3239 | 0.170 |
Why?
|
| Happiness | 1 | 2019 | 10 | 0.160 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2019 | 9 | 0.160 |
Why?
|
| Female | 13 | 2024 | 65598 | 0.160 |
Why?
|
| Depressive Disorder, Major | 2 | 2019 | 400 | 0.160 |
Why?
|
| Meningoencephalitis | 1 | 2019 | 19 | 0.160 |
Why?
|
| Dietary Supplements | 1 | 2023 | 475 | 0.160 |
Why?
|
| Cerebellum | 1 | 2023 | 414 | 0.160 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2023 | 1078 | 0.160 |
Why?
|
| Autoimmune Diseases of the Nervous System | 1 | 2019 | 31 | 0.160 |
Why?
|
| Self Report | 2 | 2020 | 517 | 0.160 |
Why?
|
| Glial Fibrillary Acidic Protein | 1 | 2019 | 104 | 0.160 |
Why?
|
| Evoked Potentials | 1 | 2019 | 139 | 0.150 |
Why?
|
| Anisotropy | 2 | 2022 | 122 | 0.150 |
Why?
|
| Students | 1 | 2020 | 254 | 0.150 |
Why?
|
| Bayes Theorem | 1 | 2019 | 280 | 0.150 |
Why?
|
| Fear | 1 | 2019 | 201 | 0.140 |
Why?
|
| Psychotropic Drugs | 3 | 2010 | 124 | 0.140 |
Why?
|
| Anxiety | 2 | 2021 | 961 | 0.140 |
Why?
|
| Psychiatric Status Rating Scales | 3 | 2010 | 805 | 0.140 |
Why?
|
| Astrocytes | 1 | 2019 | 250 | 0.130 |
Why?
|
| Autoantibodies | 1 | 2019 | 424 | 0.130 |
Why?
|
| Diffusion Tensor Imaging | 2 | 2022 | 238 | 0.130 |
Why?
|
| Hospitals, Pediatric | 1 | 2020 | 781 | 0.130 |
Why?
|
| Autism Spectrum Disorder | 1 | 2021 | 377 | 0.130 |
Why?
|
| Young Adult | 4 | 2022 | 8867 | 0.120 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2023 | 3549 | 0.110 |
Why?
|
| Electronic Health Records | 1 | 2021 | 711 | 0.110 |
Why?
|
| Biomarkers | 1 | 2023 | 2951 | 0.110 |
Why?
|
| Antidepressive Agents | 2 | 2024 | 288 | 0.100 |
Why?
|
| Surveys and Questionnaires | 4 | 2024 | 3680 | 0.090 |
Why?
|
| Brain | 1 | 2023 | 2965 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 228 | 0.090 |
Why?
|
| Child of Impaired Parents | 1 | 2010 | 15 | 0.090 |
Why?
|
| Severity of Illness Index | 2 | 2010 | 2852 | 0.080 |
Why?
|
| Mental Disorders | 3 | 2005 | 826 | 0.080 |
Why?
|
| Family Health | 1 | 2010 | 259 | 0.080 |
Why?
|
| Violence | 3 | 2021 | 115 | 0.070 |
Why?
|
| Treatment Outcome | 5 | 2011 | 12165 | 0.070 |
Why?
|
| Cyclothymic Disorder | 1 | 2006 | 3 | 0.070 |
Why?
|
| Dysthymic Disorder | 1 | 2006 | 6 | 0.070 |
Why?
|
| Patient Selection | 1 | 2010 | 683 | 0.070 |
Why?
|
| Triazines | 1 | 2006 | 29 | 0.060 |
Why?
|
| Kindling, Neurologic | 1 | 2005 | 13 | 0.060 |
Why?
|
| Defense Mechanisms | 1 | 2005 | 13 | 0.060 |
Why?
|
| Psychotherapy | 2 | 2024 | 227 | 0.060 |
Why?
|
| Life Change Events | 1 | 2005 | 59 | 0.060 |
Why?
|
| Risk Factors | 4 | 2010 | 10036 | 0.060 |
Why?
|
| Affect | 1 | 2006 | 158 | 0.060 |
Why?
|
| Child, Preschool | 2 | 2019 | 13918 | 0.060 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2006 | 174 | 0.060 |
Why?
|
| Personality Inventory | 1 | 2005 | 166 | 0.060 |
Why?
|
| Glutamic Acid | 1 | 2006 | 200 | 0.060 |
Why?
|
| Models, Psychological | 1 | 2005 | 138 | 0.060 |
Why?
|
| Comorbidity | 2 | 2006 | 1498 | 0.060 |
Why?
|
| Immunoglobulins, Intravenous | 1 | 2024 | 141 | 0.060 |
Why?
|
| Adult | 5 | 2024 | 29079 | 0.050 |
Why?
|
| Social Adjustment | 1 | 2003 | 85 | 0.050 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2024 | 303 | 0.050 |
Why?
|
| Adaptation, Psychological | 1 | 2005 | 461 | 0.050 |
Why?
|
| Prospective Studies | 2 | 2010 | 6030 | 0.050 |
Why?
|
| Endophenotypes | 1 | 2021 | 13 | 0.050 |
Why?
|
| Kynurenic Acid | 1 | 2020 | 8 | 0.050 |
Why?
|
| Logistic Models | 1 | 2005 | 1801 | 0.040 |
Why?
|
| Amygdala | 1 | 2021 | 81 | 0.040 |
Why?
|
| Tryptophan | 1 | 2020 | 90 | 0.040 |
Why?
|
| Impulsive Behavior | 1 | 2021 | 144 | 0.040 |
Why?
|
| Anxiety Disorders | 2 | 2021 | 677 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2022 | 756 | 0.040 |
Why?
|
| Neuropsychological Tests | 1 | 2021 | 927 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5049 | 0.030 |
Why?
|
| Mass Screening | 1 | 2022 | 788 | 0.030 |
Why?
|
| Cognition | 1 | 2021 | 739 | 0.030 |
Why?
|
| Age Factors | 3 | 2010 | 2806 | 0.030 |
Why?
|
| Pediatrics | 1 | 2005 | 1142 | 0.030 |
Why?
|
| Double-Blind Method | 2 | 2011 | 1601 | 0.030 |
Why?
|
| Prevalence | 1 | 2020 | 2407 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 1100 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2024 | 2397 | 0.030 |
Why?
|
| Retrospective Studies | 2 | 2010 | 16056 | 0.030 |
Why?
|
| California | 1 | 2010 | 127 | 0.020 |
Why?
|
| Age of Onset | 1 | 2010 | 581 | 0.020 |
Why?
|
| Parent-Child Relations | 1 | 2010 | 250 | 0.020 |
Why?
|
| Social Behavior Disorders | 1 | 2006 | 12 | 0.020 |
Why?
|
| Juvenile Delinquency | 1 | 2006 | 23 | 0.020 |
Why?
|
| Family Therapy | 1 | 2006 | 34 | 0.020 |
Why?
|
| United States | 1 | 2020 | 10663 | 0.020 |
Why?
|
| Central Nervous System Stimulants | 1 | 2006 | 125 | 0.020 |
Why?
|
| Drug Compounding | 1 | 2005 | 34 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2006 | 234 | 0.020 |
Why?
|
| Expert Testimony | 1 | 2005 | 36 | 0.020 |
Why?
|
| Psychotic Disorders | 1 | 2006 | 139 | 0.010 |
Why?
|
| Patient Education as Topic | 1 | 2006 | 453 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2006 | 1142 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 679 | 0.010 |
Why?
|
| Patient Care Team | 1 | 2006 | 547 | 0.010 |
Why?
|
| Autistic Disorder | 1 | 2005 | 346 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2010 | 4705 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2010 | 3079 | 0.010 |
Why?
|